Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands

ME Hagendijk, S van der Schans, C Boersma, MJ Postma, S van der Pol

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)991-999
Number of pages9
JournalEuropean Journal of Health Economics
Issue number6
Publication statusPublished - Aug 2021


  • Economic evaluation
  • Lu-177-DOTATATE
  • Lutetium-Octreotate
  • Neuroendocrine tumour
  • Octreotide long-acting release

Cite this